The risk of venous thromboembolism (VTE) associated with the use of chlormadinone acetate (CMA) is currently unknown as the available data have significant limitations and lack data on direct comparison between levonorgestrel (LNG) and CMA containing COCs. This new study is designed to assess the VTE risk associated with CMA containing COCs compared to LNG containing COCs in a large case-control study.